Items tagged with Scientific research
A computational model to understand the dynamics of tuberculosis lesions within the lungs (post)
The researchers of the Experimental Tuberculosis Unit of the Germans Trias i Pujol Research Institute (IGTP), led by Pere-Joan Cardona, have published the first results of a computational model that aims to reproduce the dynamics of tuberculosis lesions in a virtual lung. The model has been developed within the 3Rs Program of the Centre for Comparative Medicine and Bioimaging (CMCiB) of the IGTP, supported by the "la Caixa" Foundation.
Stem cells are the marrow of the TB pandemic, which still kills one person every 22 seconds (post)
A new study finds that not only can stem cells be targeted for protective vaccination, but they can also be hijacked by a pathogen to increase TB virulence.
Solving a mystery: How the TB bacterium develops rapid resistance to antibiotics (post)
These slow growing bacteria have long puzzled TB researchers. Turns out the answer lies in the epigenetic domain.
Lung-on-chip provides new insight on body's response to early TB infection (post)
Scientists have developed a lung-on-chip model to study how the body responds to early tuberculosis (TB) infection, according to findings published today in eLife.
Scientists discover potential method to starve the bacteria that cause TB (post)
By deepening our understanding of how Tuberculosis bacteria feed themselves, University of Guelph researchers have identified a potential target for drug treatment. The team used the Canadian Light Source (CLS) at the University of Saskatchewan to image the bacteria in fine detail.
Hit movie reveals how a TB drug halts ATP synthesis (post)
Structural data revealing how an anti-tuberculosis drug works could aid efforts to improve therapeutic options for the disease. The findings also uncover aspects of how the drug’s target, the ATP synthase enzyme, operates.
Sub-clinical TB: Fascinating South African research helps push frontiers of TB science (post)
As much as 80% of adults in the Western Cape may at some point have been infected with the tuberculosis (TB) bacterium. While estimates are uncertain, rates are believed to be high in the rest of the country as well, with likely millions of people having been infected with TB. Most people’s bodies, however, manage to suppress the infection and they do not actually fall ill. People who have been infected but who do not fall ill are traditionally classified as having latent TB infection.
Using viruses to kill TB bacteria (post)
Viruses are infamous for the infectious diseases they cause in different organisms — the year 2020 has proved it for us to see. But, a virus that causes an infection in one organism could be harmless in another. The Nipah virus, for example, is harmless in bats but causes a deadly disease in humans. Likewise, there are a group of viruses called bacteriophages that infect and kill bacteria but are generally harmless in humans. Within this group of viruses are myriad individuals, each one specific to certain bacteria.
Amgen licenses AMG 634, an investigational treatment for TB and leprosy, to Medicines Development for Global Health (post)
THOUSAND OAKS, Calif. and MELBOURNE, Australia, Dec. 22, 2020 -- Amgen (NASDAQ:AMGN) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the companies have entered into a license agreement for AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor being investigated for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy. The compound is in Phase 2 development with studies led by the Aurum Institute NPC (TB study) and The Leprosy Mission Nepal (ENL study). Amgen had acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla® (apremilast) from Celgene in 2019. Under the terms of the agreement, MDGH will assume full responsibility for the further development and commercialization of AMG 634.
Resist the resistance: Fighting the good fight against bacteria (post)
UNIVERSITY PARK, Pa. — Drug-resistant bacteria could lead to more deaths than cancer by 2050, according to a report commissioned by the United Kingdom in 2014 and jointly supported by the U.K. government and the Wellcome Trust. In an effort to reduce the potential infection-caused 10 million deaths worldwide, Penn State researcher Scott Medina has developed a peptide, or small protein, that can target a specific pathogen without damaging the good bacteria that bolsters the immune system.
Page 51 of 74 · Total posts: 0
←First 50 51 52 Last→